Q-omics provides the consensus-scored ZNF503 profile across patient tissues and cancer cell-line models. ZNF503 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF503 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ZNF503 RNA expression shows 17,773 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where ZNF503 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF503 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF503 survival associations across molecular data types. ZNF503 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF503 RNA expression–survival associations across cancer types. High ZNF503 expression shows unfavorable associations in ACC, KIRP, LGG, BLCA and CESC, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF503 RNA expression.
This table summarizes ZNF503 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF503. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF503 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in HNSC, LIHC and COAD. The KIRC box plot shows higher ZNF503 RNA expression in normal versus tumor tissue (log2 FC = −1.954, t-test p < 0.001).
This table shows molecular features associated with ZNF503 in patient tissues and cancer cell lines. In patient samples, ZNF503 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF503 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
